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Purpose
There is no standard second-line regimen for malignant melanoma patients with disease
progression after first-line chemotherapy, and platinum-alkylating agents combined with
paclitaxel have shown modest efficacy.
Materials and Methods
We conducted a phase II, open-label, single-arm study to test the efficacy of docetaxel 
combined with carboplatin for malignant melanoma patients who failed previous treatment
with dacarbazine. Intravenous docetaxel (35 mg/m2 on days 1 and 8 of each cycle) and
carboplatin (area under the curve 3 on days 1 and 8 of each cycle) was administered every
21 days. Primary end point was objective response rate (ORR). 
Results
Thirty patients were enrolled in the study, and the median follow-up duration was 19.8
months. Among 25 per-protocol patients, there were three responders (1 with complete 
response and 2 with partial response) and 17 stable disease patients (ORR, 12.0%). Among
the per-protocol population, the median progression-free survival (PFS) was 4.3 months
and the median overall survival (OS) was 9.6 months. Uveal melanoma patients (n=9)
showed the best prognosis compared to other subtypes (median PFS, 7.6 months; OS, 9.9
months). The most common grade 3 or 4 adverse event was neutropenia (n=15, 50.0%).
Conclusion
Docetaxel combined with carboplatin showed association with an acceptable safety profile
and overall efficacy for patients with malignant melanoma who had progressed on
chemotherapy containing dacarbazine. 
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Introduction
The incidence of melanoma has shown a rapid increase,
with 76,100 estimated new cases and 9,710 estimated deaths
per year in the United States in 2014 [1]. Geographic and 
ethnic differences for malignant melanoma have been 
reported between Asian and Caucasian patients [2]. The 
incidence of melanoma in Asia is rare, with an incidence rate
of 0.2 to 0.5 per 100,000 patients per year. In Asian popula-
tions approximately 65% of all cases are mucosal and acral
melanomas, whereas melanoma of the skin on the trunk and
legs is the most common in Caucasian populations [3]. 
New targeted and immunotherapeutic agents have 
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recently been approved for the initial management of 
patients with stage IV melanoma, including vemurafenib,
dabrafenib, and trametinib for patients with the V600 
mutated BRAF gene, and immune checkpoint inhibitors such
as ipilimumab and nivolumab. In Asia, because acral or 
mucosal melanoma patients harboring the V600 mutated
BRAF gene are rarely seen, many malignant melanoma 
patients are not eligible for treatment with BRAF targeting
agents. In addition, owing to cost and insurance coverage,
many patients cannot afford immune checkpoint inhibitors.
Among many immunotherapeutic and cytotoxic chemot-
herapeutic agents evaluated as systemic treatment for
metastatic melanoma, only two were approved for metastatic
melanoma before 2011: high-dose interleukin-2 (IL-2) and
dacarbazine. High-dose IL-2 has been shown to induce
durable remission for some patients, but it is one of the most
toxic cancer treatments. Thus, dacarbazine is usually offered
as first-line chemotherapy to most malignant melanoma 
patients, especially in Asia. However, the response rates
(RRs) for both therapies are only 10% to 20%, and neither is
thought to improve overall survival (OS) [4,5]. 
There is no standard second-line regimen for malignant
melanoma patients with disease progression after first-line
chemotherapy, even though progression-free survival (PFS)
is short in malignant melanoma. Other cytotoxic agents have
been investigated, including the combination of platinum-
alkylating agents and paclitaxel, which has demonstrated
modest antitumor activity against malignant melanoma in
various clinical trials with a median PFS of 3 to 4 months and
RR of 11% to 26% [6,7]. The toxicity profiles of these agents
do not overlap. Docetaxel has shown antitumor efficacy in
vitro [8,9], and some studies have reported that it is a more
potent antiangiogenesis agent than paclitaxel [10,11]. 
However, no prospective study to evaluate the efficacy of
platinum-alkylating agents combined with docetaxel for 
malignant melanoma has been reported.
The aim of this study was to assess the efficacy of docetaxel
combined with carboplatin as second-line treatment in 
malignant melanoma patients who failed first-line dacar-
bazine or temozolomide therapy.
Materials and Methods
1. Patients
Eligible patients were at least 20 years old and had histo-
logically confirmed malignant melanoma (recurred or
metastatic) that had progressed during or after at least one
cycle of a dacarbazine- or temozolomide-containing regimen
in the advanced setting. Additional eligibility criteria 
included Eastern Cooperative Oncology Group (ECOG) 
performance status of 0 to 2; at least one measurable lesion
by computed tomography (CT) according to Response Eval-
uation Criteria in Solid Tumors (RECIST) ver. 1.1; adequate
bone marrow, liver, and renal function; and life expectancy
of at least 12 weeks. Exclusion criteria were as follows: preg-
nancy or breast feeding; symptomatic brain metastasis; 
previous history of treatment with chemotherapy containing
taxane or platinum agents; major surgery within 2 weeks 
before the start of the trial or failure to recover from a 
surgery; previous history of other malignancies within 5
years except for cured skin basal cell carcinoma or cured in
situ cervix cancer; other severe medical conditions including
uncontrolled infection, uncontrolled hypertension, heart fail-
ure, and myocardial infarction history within 6 months; 
sensitivity to platinum agents or docetaxel; uncontrolled
seizure; and alcohol or drug abuse.
2. Study design and end points
The current phase II, open-label, single-arm study was 
conducted in a single center, Yonsei Cancer Center, Seoul,
Korea. Intravenous docetaxel (35 mg/m2 on days 1 and 8 of
each cycle) and carboplatin (area under the curve 3 on days
1 and 8 of each cycle) were administered every 21 days. 
Dexamethasone (8 mg) was administered orally or intra-
venously 30 minutes before docetaxel infusion to prevent
fluid retention. Study treatment was continued until unac-
ceptable toxicity, tumor progression, patient death, or with-
drawal of patient consent. The primary end point of this
study was objective response rate (ORR). The secondary end
points were disease control rate (DCR), PFS, OS, and safety.
Tumor response and disease progression were evaluated 
according to RECIST ver. 1.1 guideline. Tumors were 
assessed radiographically using CT every two cycles (every
6 weeks) during the treatment period. Patients who discon-
tinued study treatment were followed every 3 months for 1
year, and every 6 months for the following year, or until
death, for collection of data on OS. The National Cancer 
Institute’s Common Terminology Criteria for Adverse
Events ver. 4.0 was used to grade adverse events and to 
determine the need for dose modifications. The doses of 
docetaxel and carboplatin were reduced by 20% following
the occurrence of grade 4 neutropenia lasting more than 7
days, grade 4 thrombocytopenia, febrile neutropenia, or any
grade 3 or 4 nonhematologic toxicity. The protocol was 
approved by the Institutional Review and Ethics Board of 
Severance Hospital, Seoul, Korea. The study was conducted
in accordance with the Declaration of Helsinki and the Good
Clinical Practice Guidelines defined by the International
Conference on Harmonization. All patients provided written
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informed consent before enrollment. The trial is registered at
ClinicalTrials.gov (NCT02223884).
3. Statistical analyses
The safety population included all patients who received
at least one dose of study drug (intent-to-treat population).
For efficacy endpoints, primary analyses were performed in
the per-protocol patients who at least completed treatment
until the first response evaluation. For calculation of sample
size, Simon’s two-stage minimax design was applied to test
the null hypothesis of 5% as opposed to the alternative 
hypothesis of 20%. Assuming an !-error of 0.05 and a "-error
of 0.2, 13 evaluable patients had to be accrued during stage
1, and if at least one patient responded with complete or 
partial response, 14 additional patients were to be enrolled
in the study during stage 2. A sample size of 30 patients was
planned, allowing for a 10% dropout rate. Kaplan-Meier 
estimates and Cox regression analyses of DFS and OS were
calculated. All reported p-values were two-sided. Data were




Between September 2011 and April 2014, 30 malignant
melanoma patients who failed chemotherapy containing
dacarbazine were enrolled in the study (Fig. 1). Patient 
demographics and baseline disease characteristics are 
described in Table 1. Most of the patients had an ECOG 
performance status of 0 (73.3%), and about half of them had
liver (46.7%) or lung metastasis (50.0%). BRAFV600 mutation
was found in five patients (16.7%) and c-Kit mutation in two
(6.7%). Prior to study enrollment, each patient had received
Enrolled (n=30)
Analyzed as per-protocol (n=25)
Every patients started the treatment
  Analyzed as intention to treat
  (n=30)
Patients who could not complete
  treatment until the first response
  evaluation (n=5)
  - Death before first response
      evaluation (n=2)
  - Clinical disease progression after
      first cycle (n=2)
  - Follow-up loss after first cycle
      (n=1)
Fig. 1.  Study flow diagram.
Table 1. Baseline patient demographic and clinical char-
acteristics (n=30)
Characteristic No. (%)













Lactate dehydrogenase level at baseline
Normal 14 (46.7)
Above normal 16 (53.3)
Liver metastasis 14 (46.7)
Lung metastasis 15 (50.0)
BRAF mutation
Wild type 25 (83.3)
V600E 5 (16.7)
c-Kit mutation
Wild type 14 (46.7)
Exon 11 mutation 2 (6.7)
Not evaluated 14 (46.7)
Previous chemotherapy regimen
Dacarbazine 26 (86.7)
Dacarbazine and vemurafenib 3 (10.0)
Cisplatin/vinblastine/dacarbazine 1 (3.3)
Previous radiotherapy 15 (50.0)
ECOG, Eastern Cooperative Oncology Group; CSD,
chronic sun damage.
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at least one chemotherapy regimen containing dacarbazine.
Half of the patients had undergone previous radiotherapy.
Patients’ melanomas were categorized according to their
locations and degree of exposure to the sun [12] as follows:
those arising from the skin with chronic sun-induced (CSD) 
damage (CSD melanoma), those occurring on the skin with-
out chronic sun-induced damage (non-CSD melanoma),
those found on sun-protected skin areas such as the palms,
soles, or subungual sites (acral melanomas), and those on
mucosal membranes (mucosal melanomas). In addition to
these four subtypes, patients with ocular melanomas were
also treated in this study. Because there are significant dif-
ferences in molecular pathogenesis between uveal (choroi-
dal) and conjunctival melanomas [13], the two conditions
were analyzed separately. In our study cohort, the most com-
mon melanoma subtype was uveal melanoma (n=10, 33.3%),
Table 2. Results of therapy based on response (per-protocol population, n=25a))
Variable All patients Responders SD PD p-value (n=25) (n=3) (n=17) (n=5)
ECOG performance status 0.357
0 20 (80.0) 3 (100) 14 (82.4) 3 (60.0)
1 5 (20.0) 0 ( 3 (17.6) 2 (40.0)
Tumor subtype 0.083
Skin 5 (20.0) 1 (33.3) 2 (11.8) 2 (40.0)
Acral 5 (20.0) 2 (66.7) 2 (11.8) 1 (20.0)
Mucosal 6 (24.0) 0 ( 4 (23.5) 2 (40.0)
Choroidal 9 (36.0) 0 ( 9 (52.9) 0 (
LDH level at baseline 0.599
Normal 13 (52.0) 1 (33.3) 10 (58.8) 2 (40.0)
Above normal 12 (48.0) 2 (66.7) 7 (41.2) 3 (60.0)
Liver metastasis 12 (48.0) 0 ( 10 (58.8) 2 (40.0) 0.158
Lung metastasis 13 (52.0) 2 (66.7) 9 (52.9) 2 (40.0) 0.758
BRAF mutation 0.620
Wild type 21 (84.0) 2 (66.7) 15 (88.2) 4 (80.0)
V600E 4 (16.0) 1 (33.3) 2 (5.9) 1 (20.0)
c-Kit mutation 0.257
Wild type 13 (52.0) 2 (66.7) 8 (47.1) 3 (60.0)
Exon 11 mutation 1 (4.0) 0 ( 0 ( 1 (20.0)
Not evaluated 11 (44.0) 1 (33.3) 9 (52.9) 1 (20.0)
Previous chemotherapy regimen 0.461
Dacarbazine 22 (88.0) 2 (66.7) 15 (88.2) 5 (100)
Dacarbazine and vemurafenib 2 (8.0) 1 (33.3) 1 (5.9) 0 (
Cisplatin/vinblastine/dacarbazine 1 (4.0) 0 ( 1 (5.9) 0 (
Previous radiotherapy 11 (44.0) 2 (66.7) 6 (35.3) 3 (60.0) 0.434
Median chemotherapy cycles (range) 5.5 (2-12) 8 (8-12) 6 (2-12) 2 (2)
Median progression-free survival (mo) 4.3 ( 6.0 ( 4.9 ( 1.3 ( < 0.001
Median overall survival (mo) 9.6 ( 9.6 ( 9.9 ( 5.9 ( 0.194
Values are presented as number (%) unless otherwise indicated. SD, stable disease; PD, progressive disease; ECOG, Eastern















5 10 15 20 25
OS (median, 9.6 mo)
PFS (median, 4.3 mo)
Fig. 2.  Survival analysis. Kaplan-Meier curves for 
progression-free survival (PFS) and overall survival (OS)
of per-protocol patients (n=25).
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followed by mucosal melanoma (n=7, 23.3%), non-CSD
melanoma (n=6, 20.0%), acral melanoma (n=5, 16.7%), and
conjunctival melanoma (n=2, 6.7%). Among non-CSD and
conjunctival melanoma patients, four out of eight patients
(50.0%) had BRAF V600 mutations, which is comparable to
the known incidence (approximately 40% to 60%). Among
acral and mucosal melanoma patients, one out of 12 patients
(8.3%) had BRAF V600 mutation, which is also comparable
to the known incidence (less than 10%).
2. Efficacy analysis
The median follow-up duration was 19.8 months. At the
cut-off date for data collection on August 20, 2014, one 
patient with uveal melanoma was still receiving on-going
treatment. Of the 30 enrolled patients, 25 (83.3%) could be
evaluated for tumor response as five patients did not receive
treatment until the first response evaluation. In the intent-
to-treat population (n=30), the median PFS was 3.7 months,
and the median OS was 9.4 months. In the per-protocol 
population, the median PFS was 4.3 months (22 PFS events
among 25 patients), and the median OS was 9.6 months (16
OS events among 25 patients) (Fig. 2). Among 25 per-proto-
col patients, there were three responders (1 with complete
response [CR] and 2 with partial response [PR]) and 17 
patients with stable disease (SD). The ORR was 12.0% (n=3;
95% confidence interval [CI], 0% to 24.74%), and DCR was
80.0% (n=20; 95% CI, 64.32% to 95.68%). All deaths were 
cancer-related. No statistically significant differences were
observed among responders, patients with SD, and those
with progression regarding ECOG performance status,
tumor subtype, lactate dehydrogenase (LDH) level at base-
line, liver or lung metastasis, BRAF or c-Kit mutation, previ-
ous chemotherapy regimen, and history of previous
radiotherapy (Table 2). Responders had significantly longer
median PFS (6.0 months vs. 4.9 months vs. 1.3 months, 
respectively; p < 0.001). ECOG performance status (hazard
ratio [HR], 5.399; 95% CI, 1.661 to 17.549; p=0.005) and LDH
level at baseline (HR, 4.331; 95% CI, 1.454 to 12.898; p=0.008)
were the only two covariates showing association with worse
PFS (Table 3). Age, sex, BRAF or c-Kit mutation status, liver
or lung metastasis, and previous radiotherapy did not show
statistical association with either PFS or OS.
Prognosis and demographics differed according to malig-
Table 3. Univariate analysis of PFS and OS (per-protocol analysis, n=25)
Parameter No. (%) PFS OS
HR 95% CI p-value HR 95% CI p-value
Age (yr)
< 60 20 (80.0) Reference Reference
! 60 5 (20.0) 2.170 0.746-6.310 0.155 0.931 0.296-2.929 0.903
Gender
Female 8 (32.0) Reference Reference
Male 17 (68.0) 1.731 0.665-4.504 0.261 3.273 0.907-11.819 0.070
ECOG
0 20 (80.0) Reference Reference
1 5 (20.0) 5.399 1.661-17.549 0.005 1.409 0.481-4.130 0.532
LDH level at baseline
Normal 13 (52.0) Reference Reference
Above normal 12 (48.0) 4.331 1.454-12.898 0.008 1.917 0.710-5.473 0.193
BRAF
Wild type 21 (84.0) Reference Reference
V600E 4 (16.0) 0.890 0.260-3.049 0.853 0.867 0.243-3.094 0.825
c-Kita)
Wild type 13 (52.0) Reference Reference
Exon 11 mutation 1 (4.0) 3.890 - 0.240 4.947 - 0.195
Liver metastasis 12 (48.0) 1.105 0.477-2.559 0.815 1.483 0.519-4.237 0.462
Lung metastasis 13 (52.0) 0.783 0.338-1.814 0.568 1.013 0.364-2.815 0.980
Previous radiotherapy 11 (44.0) 0.866 0.371-2.025 0.740 1.041 0.440-2.463 0.927
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative
Oncology Group; LDH, lactate dehydrogenase. a)Only 14 patients underwent c-Kit mutation analysis.
nant melanoma subtypes (Table 4). Uveal melanoma patients
(n=9) had the best prognosis when treated with docetaxel
plus carboplatin compared to those with other subtypes 
(median PFS, 7.6 months; OS, 9.9 months). All patients with
uveal melanoma had the best response as SD. Uveal
melanoma patients also experienced a high incidence of liver
metastasis (n=8, 88.9%) with no BRAF or c-Kit mutation. 
Patients with acral melanoma (n=5), another melanoma 
subtype that is abundant in Asia, had better OS (median OS,
9.6 months) than those with non-CSD or mucosal melanoma. 
3. Treatment compliance and toxicity
The median number of treatment cycles was 4.5 (range, 1
to 15 cycles). The median relative dose intensity (RDI) was 1
(range, 0.3 to 1) for both docetaxel and carboplatin. Thirteen
patients (43.3%) had dose reduction, and treatment initiation
was delayed for 16 patients (53.3%). The most common 
reason for delay and dose reduction was neutropenia.
Most patients (n=29, 96.7%) reported at least one adverse
event related to treatment, and the total incidence of grade 3
or 4 adverse events was 66.7% (n=20) (Table 5). The most
common adverse event was neutropenia (all grades; n=20,
67.7%), with half of the patients experiencing grade 3 or 4
neutropenia (n=15, 50.0%). The incidence of grade 3 or 4 
anemia and thrombocytopenia was 10.0% (n=3) and 13.3%
(n=4), respectively. Nonhematologic toxicity was less 
common and less severe than hematologic toxicity. Observed
grade 3 or 4 nonhematologic adverse events included
anorexia (n=3, 10.0%), vomiting (n=2, 6.7%), nausea, periph-
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Table 4. Results of therapy based on tumor subtype (per-protocol population, n=25)
Variable All patients Non-CSD Acral Mucosal Uveal Conjunctival p-value(n=25) (n=5) (n=5) (n=4) (n=9) (n=2)
ECOG performance status 0.014
0 20 (80.0) 4 (80.0) 3 (60.0) 4 (100) 9 (100) 0 (
1 5 (20.0) 1 (20.0) 2 (40.0) 0 ( 0 ( 2 (100)
LDH level at baseline 0.481
Normal 13 (52.0) 3 (60.0) 2 (40.0) 3 (75.0) 5 (55.6) 0 (
Above normal 12 (48.0) 2 (40.0) 3 (60.0) 1 (25.0) 4 (44.4) 2 (100)
Liver metastasis 12 (48.0) 3 (60.0) 0 ( 1 (16.7) 8 (88.9) 0 ( 0.009
Lung metastasis 13 (52.0) 3 (60.0) 3 (60.0) 3 (75.0) 3 (33.3) 1 (50.0) 0.669
BRAF mutation 0.171
Wild type 21 (84.0) 3 (60.0) 4 (80.0) 4 (100) 9 (100.0) 1 (50.0)
V600E 4 (16.0) 2 (40.0) 1 (20.0) 0 ( 0 ( 1 (50.0)
c-Kit mutation 0.563
Wild type 13 (52.0) 1 (20.0) 4 (80.0) 2 (50.0) 5 (55.6) 1 (50.0)
Exon 11 mutation 1 (4.0) 1 (20.0) 0 ( 0 ( 0 ( 0 (
Not evaluated 11 (44.0) 3 (60.0) 1 (20.0) 2 (50.0) 4 (44.4) 1 (50.0)
Previous chemotherapy regimen 0.160
Dacarbazine 22 (88.0) 3 (60.0) 5 (100) 4 (100) 9 (100) 1 (50.0)
Dacarbazine and vemurafenib 2 (8.0) 1 (20.0) 0 ( 0 ( 0 ( 1 (50.0)
Cisplatin/vinblastine/dacarbazine 1 (4.0) 1 (20.0) 0 ( 0 ( 0 ( 0 (
Previous radiotherapy 11 (44.0) 4 (80.0) 1 (20.0) 4 (100) 1 (11.1) 1 (50.0) 0.012
Median chemotherapy cycles (range) 5.5 (2-12) 2 (2-8) 6 (2-12) 6 (2-8) 7 (4-12) 2.5 (2-3) -
Response 0.164
CR 1 (4.0) 1 (20.0) 0 ( 0 ( 0 ( 0 (
PR 2 (8.0) 0 ( 2 (40.0) 0 ( 0 ( 0 (
SD 17 (68.0) 2 (40.0) 2 (40.0) 3 (75.0) 9 (100) 1 (50.0)
PD 5 (20.0) 2 (40.0) 1 (20.0) 1 (25.0) 0 ( 1 (50.0)
Median progression-free survival (mo) 4.3 ( 1.8 ( 3.9 ( 7.1 ( 7.6 ( 1.2 ( 0.061
Median overall survival (mo) 9.6 ( 5.9 ( 9.6 ( 7.8 ( 9.9 ( 7.7 ( 0.798
Values are presented as number (%) unless otherwise indicated. CSD, chronic sun damage; ECOG, Eastern Cooperative 
Oncology Group; LDH, lactate dehydrogenase; CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease.
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eral neuropathy, epistaxis, skin ulceration, and infection
(n=1, 3.3% each). In one patient, peripheral neuropathy led
to treatment cessation (Fig. 1).
Discussion
We herein report the results of a phase II study of docetaxel
combined with carboplatin as second-line treatment for 
malignant melanoma patients experiencing disease progres-
sion on chemotherapy containing dacarbazine. Our findings
suggested that in this patient population, the combination of
docetaxel and carboplatin was a reasonable option for 
second-line treatment.
Several prospective and retrospective studies on second-
line treatment for malignant melanoma [6,14-16] have 
reported a median PFS between 1.3 and 4.1 months and OS
between 3.5 and 9.8 months. In these studies, the combina-
tion of paclitaxel and carboplatin resulted in the best survival
(PFS, 4.1 months; OS, 9.8 months) [16]. Results of our study
were comparable with those from previous reports with a
median PFS of 4.3 months and a median OS of 9.6 months.
ECOG performance status and baseline LDH level were the
two covariates with significant effects on PFS. In previous
second-line studies, the reported ORR was between 5.3% and
26.0%, whereas DCR between 18.9% and 62% was reported.
Our results showed an ORR of 12.0% and a DCR of 80%. The
treatment was also tolerable and manageable. The median
RDI was 1 for both agents. Major adverse events were hema-
tologic toxicity, and 50.0% of the patients suffered grade 3 or
4 neutropenia. Although dose reduction and delayed treat-
ment were required in about half of the patients, only one
patient had to discontinue treatment due to toxicity.
In addition to reporting the overall efficacy of the regimen,
the current study successfully demonstrated the profound
survival benefit by docetaxel combined with carboplatin in
patients with uveal melanoma. Beside non-CSD (20.0%),
acral (16.7%), mucosal (23.3%) and conjunctival melanoma
(6.7%), uveal melanoma was the most common subtype
(n=10, 33.3%). The disease represents only 3% to 5% of all
melanoma cases [17], and in the largest reported series of 
unselected cases to date, patients with metastatic uveal
melanoma had a poor prognosis with a median OS of only
3.6 months [18]. In our study, uveal melanoma was the 
subtype that showed the best survival with a median PFS of
7.6 months and OS of 9.9 months. In previously reported
clinical trials of first-line chemotherapy in uveal melanoma
[19-21], the median PFS ranged between 1.6 and 4.0 months
and OS between 7.7 and 11.8 months. Considering that our
study patients had failed at least one prior chemotherapy
regimen, the results of this study were very promising 
despite the small number of patients. On the other hand, a
phase II trial of the novel targeted agent selumetinib, a mito-
gen-activated protein kinase inhibitor, as first-line treatment
for uveal melanoma [20] reported a median PFS of 3.7
months and OS of 11.8 months. In this study, the median OS
calculated from the starting date of the first-line chemother-
apy containing dacarbazine was 13.8 months for uveal
melanoma patients. Although none of the uveal melanoma
patients in our study had CR or PR, they all had SD. Two
previous trials of first-line chemotherapy for uveal mela-
noma also reported no patients with response. Oncogenic
mutations in guanine nucleotide-binding protein G(q) 
Table 5. Incidences of treatment related adverse events
(n=30)
Treatment Grade 3 or 4 All gradesrelated adverse event
Any event 20 (67.7) 29 (96.7)
Hematologic toxicity 
Febrile neutropenia 1 (3.3) 1 (3.3)
Neutropenia 15 (50.0) 20 (67.7)
Anemia 3 (10.0) 6 (20.0)
Thrombocytopenia 4 (13.3) 7 (23.3)
Nonhematologic toxicity 
Anorexia 3 (10.0) 14 (46.7)
Nausea 1 (3.3) 13 (43.3)
Alopecia 0 ( 13 (43.3)
Diarrhea 0 ( 8 (26.7)
Myalgia 0 ( 8 (26.7)
General weakness 0 ( 7 (23.3)
Peripheral neuropathy 1 (3.3) 5 (16.7)
Vomiting 2 (6.7) 4 (13.3)
Dyspnea 0 ( 4 (13.3)
Weight loss 0 ( 4 (13.3)
Mucositis 0 ( 3 (10.0)
Abdominal pain 0 ( 2 (6.7)
Nail loss 0 ( 2 (6.7)
Pleural effusion 0 ( 2 (6.7)
Epistaxis 1 (3.3) 2 (6.7)
Skin ulceration 1 (3.3) 2 (6.7)
Weight gain 0 ( 2 (6.7)
AST elevation 0 ( 2 (6.7)
Edema 0 ( 2 (6.7)
Infection 1 (3.3) 1 (3.3)
Values are presented as number (%). Incidences of treat-
ment related adverse events with more than 5% or any 
adverse events in grade 3 or 4 are shown in the table. 
Neutropenia was the most common adverse event. AST,
aspartate aminotransferase.
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subunit alpha (GNAQ) or guanine nucleotide binding protein
(G protein), alpha 11 (Gq class) (GNA11) have been reported
in more than 80% of uveal melanomas [22,23]; however, in
our study, only one uveal melanoma patient had GNA11
Q209L mutation. None of the uveal melanoma patients in
our study had BRAF or c-Kit mutation.
Conclusion
In conclusion, our results from this phase II study indi-
cated that weekly docetaxel combined with carboplatin was
well tolerated and demonstrated overall efficacy in malig-
nant melanoma patients experiencing disease progression on
chemotherapy containing dacarbazine. In particular, the 
profound survival benefit from this combination chemother-
apy among patients with uveal melanoma subtype warrants
further clinical investigation.
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